Fisetin in Mild Alzheimer's Disease

NCT07279714 | Recruiting Phase 2

• 1 other identifier: 6705
• Study Type: interventional
• Target: 5
• Locations: 1 country
• Sites: 1

Brief Summary

This pilot study will evaluate the safety and tolerability of the natural health product, fisetin, in older adults with mild cognitive impairment or mild Alzheimer's disease dementia.

Conditions

Alzheimer s Disease; Alzheimer Dementia; Alzheimer Dementia (AD); Alzheimer Disease; Mild Cognitive Disorder; Neurocognitive Disorders, Mild; Neurocognitive Disorder

Keywords

fisetin; alzheimer's disease; safety; tolerability

Outcome Measures

Primary Outcomes (1)

• Incidence of Treatment-Emergent Adverse Events (Safety and tolerability of fisetin)

  Measured using AE reports

  30 days

Study Arms (1)

Fisetin

EXPERIMENTAL

Other: Fisetin

Interventions

Fisetin OTHER

Fisetin 20mg/kg/day

Fisetin

Eligibility Criteria

• Age: 60 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Mild cognitive impairment due to Alzheimer's disease OR mild Alzheimer Dementia
• Moca score of 11 or higher
• Stable psychotropics and cognitive enhancing medications

You may not qualify if:

• Known hypersensitivity or allergy to fisetin
• Presence of any medical condition, or abnormal routine blood test, that the investigator believes would put the subject at risk or would preclude the patient from completing all aspects of the trial
• Unstable medical disorders
• Ongoing treatment for active infection with antibiotics/antifungals
• Ongoing treatment for cancer
• Active alcohol or substance use disorder
• Recent active bleeding
• Patients taking oral anticoagulants, anti-cancer, anti-seizure medications, or other medications that could have a significant interaction with fisetin
• Use within the last month of other senolytic supplements, antioxidant supplements, natural health products
• Other neurologic or neurodegenerative conditions impacting cognition
• Active Major Depressive Episode, active suicidal thoughts or psychosis
• Any thing that would preclude the ability to undergo an MRI scan

Sponsors & Collaborators

• Sunnybrook Health Sciences Centre: lead
• Sunnybrook Research Institute: collaborator

Study Sites (1)

Sunnybrook Research Institute

Toronto, Ontario, M4N 3M5, Canada

RECRUITING

MeSH Terms

Conditions

Alzheimer Disease; Neurocognitive Disorders

Interventions

fisetin

Condition Hierarchy (Ancestors)

Dementia; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Tauopathies; Neurodegenerative Diseases; Mental Disorders

Study Officials

• Krista Lanctôt, PhD

  Sunnybrook Research Institute

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Coordinator

CONTACT

416-480-6100; memoryresearch@sunnybrook.ca

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 17, 2025
• First Posted: December 12, 2025
• Study Start: January 27, 2026
• Primary Completion (Estimated): November 1, 2026
• Study Completion (Estimated): November 1, 2026
• Last Updated: April 13, 2026

Record last verified: 2025-12

Locations

CA (1)